Respiratory Panel Testing Market

Respiratory Panel Testing Market (Specimen Type: Viruses and Bacteria; Panel Type and End-user) - Europe and Middle East & Africa Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

Europe and Middle East & Africa Respiratory Panel Testing Market Outlook 2031

  • The Europe and Middle East & Africa respiratory panel testing market was valued over US$ 1.6 Bn in 2020
  • It is estimated to expand at a CAGR of 5.1% from 2021 to 2031
  • The Europe and Middle East & Africa respiratory panel testing market is expected to surpass the value of US$ 3.1 Bn by the end of 2031

Analysts’ Viewpoint on Europe and Middle East & Africa Respiratory Panel Testing Market Scenario

Healthcare brands in the Europe and Middle East & Africa respiratory panel testing market are unlocking value-grab opportunities through eCommerce to keep economies running during the ongoing COVID-19 pandemic. However, several respiratory pathogens can cause nearly indistinguishable symptoms. Hence, manufacturers should develop panels that provide fast and comprehensive results with a run time of less than an hour. Quick turnaround on a broad menu of pathogens may also help clinicians make vital decisions regarding admission, isolation, and additional diagnostic testing. The high prevalence of seasonal influenza, human rhinovirus, and viral infections is fueling the demand for respiratory panel testing. High sensitivity and specificity is preferred in respiratory panels.

CE-marked Respiratory Panels Improving Patient Outcomes

Rapid and automated detection of pathogens is significantly changing in the Europe and Middle East & Africa respiratory panel testing market. There is a demand for panels that test multiple viruses and bacteria that cause respiratory tract infections. Manufacturers are increasing the availability of panels that eliminate the need for precise measuring or pipetting. Fast turnaround time is preferred in respiratory panel testing.

High sensitivity and specificity in respiratory panel testing is helping to boost product sales. Panels based on TGA (Therapeutic Goods Administration)-certified multiplex PCR (polymerase chain reaction) systems are boosting the credibility of healthcare brands. FDA-cleared and CE marked panels are helping to improve patient outcomes.

Request a sample to get extensive insights into the Respiratory Panel Testing Market

FDA De Novo-authorized Panels Gain Demand for Diagnosis of COVID-19 Pathogens

SARS-CoV-2 has become a top concern for patients and healthcare practitioners. Companies in the Europe and Middle East & Africa respiratory panel testing market are increasing the availability of products to reduce the stress of clinicians. However, several respiratory pathogens can cause nearly indistinguishable symptoms. Hence, companies are increasing R&D investment to develop FDA De Novo authorized panels that help clinicians to quickly diagnose respiratory infections, including COVID-19, RSV, influenza, and the likes.

Manufacturers in the Europe and Middle East & Africa respiratory panel testing market are developing products that use a syndromic approach to accurately detect and identify the pathogens most commonly associated with respiratory infections. These panels are being used in combination with rapid respiratory PCR test results to enable better-informed diagnosis and treatment of patients.

To understand how our report can bring difference to your business strategy, Ask for a brochure

Multiplex PCR-based Respiratory Viral Panels Provide Prompt Results

PCR-based panels are increasingly replacing viral culture to detect pathogens. However, companies in the Europe and Middle East & Africa respiratory panel testing market should increase the availability of products to support pathogen detection, which is useful for clinicians and clinical microbiologists. PCR-based panels are emerging as an alternative to viral culture, since the latter is slow and labor-intensive. These panels are gaining popularity for the detection of viral nucleic acids and provide prompt results with high sensitivity & specificity.

Manufacturers are boosting the production for multiplex PCR-based respiratory viral panels for the test of influenza, respiratory syncytial virus (RSV), and rhinovirus, among others.

Stuck in a neck-to-neck competition with other brands? Request a custom report on Respiratory Panel Testing Market

High Prevalence of Lower RTIs Fueling Demand for Respiratory Panel Testing

The high prevalence of both self-limiting upper respiratory tract infections (RTIs) and more severe lower RTIs such as bronchitis & pneumonitis is fueling the demand for respiratory panel testing. It has been found that lower RTIs are a major cause for hospitalization, morbidity, and mortality in infants and the elderly. In order to reduce their treatment cost, respiratory panel testing is emerging as an effective strategy.

Nasopharyngeal Swabs & Home Testing Fulfill Convenience Needs of Individuals

Companies in the Europe and Middle East & Africa respiratory panel testing market are capitalizing on incremental opportunities, since PCR-based panels are a preferred option for the evaluation of severely immunocompromised patients with respiratory symptoms. The high prevalence of parainfluenza, human metapneumovirus (hMPV), and adenovirus is driving the demand for respiratory panel products.

In order to tap revenue opportunities through eCommerce, manufacturers in the Europe and Middle East & Africa respiratory panel testing market are developing products that help to collect specimens through nasopharyngeal swab. The growing trend of home testing provided by labs is another driver contributing to market growth. The Europe and Middle East & Africa respiratory panel testing market is expanding due to product demand for testing human rhinovirus and human metapneumovirus, among others.

Europe and Middle East & Africa Respiratory Panel Testing Market: Overview

  • Respiratory panel testing is a diagnostic testing panel used for the detection of pathogens in the respiratory tract. The pathogen can be a virus, bacteria, and other organism, which affects the nose, throat, and lungs, and causes breathing issues.
  • Respiratory panel testing detects various viruses including adenovirus, flu, coronavirus, and other deadly viruses. The panel requires a single sample to run various tests for diagnosis of viruses and bacteria. Various testing panels offered by the key players are rapid and automatic for faster detection of the various viruses, such as SARS-CoV-2, in a short time.

Europe and Middle East & Africa Respiratory Panel Testing Market: Key Drivers

  • Rise in prevalence of hospital-acquired infections, increase in cases of coronavirus outbreak, and surge in asthma & COPD cases are projected to drive the respiratory panel testing market in EMEA. Availability of novel and cost-efficient respiratory disease testing devices, kits, software, and consumables will aid early diagnosis of these diseases. According to the European Centre for Disease Prevention and Control (ECDC) data, 3.1 million to 4.6 million patients acquire hospital-acquired infections every year.
  • Launch of innovative COVID-19 kits & products and collaborations among key players are the other factors propelling the market in EMEA. In September 2020, DiaSorin received CE Mark for the addition of saliva specimens for use with the Simplexa COVID-19 Direct assay. In February 2020, altona Diagnostics GmbH launched the RealStar SARS-CoV-2 RT-PCR Kit 1.0. The assay is based on real-time RT-PCR technology for the detection of SARS-CoV-2 (previously 2019-nCoV), which is the causative agent of coronavirus disease 2019 (COVID-19). In July 2017, Anatolia Geneworks launched Bosphore Respiratory Pathogens Panel Kit v1. These strategic steps taken by key players are expected to augment the market during the forecast period.

Market Segmentation: Europe and Middle East & Africa Respiratory Panel Testing Market

  • In terms of specimen type, the respiratory panel testing market in EMEA has been bifurcated into viruses and bacteria. The viruses segment has been split into adenovirus, SARS-CoV-2, RSV, human metapneumo virus, rhinovirus/enterovirus, parainfluenza, virus flu A, coronavirus, flu B, HIN1 2009, and others.
  • Majority of countries struggling with viral infections are in Central and Eastern Europe. The Czech Republic, a central European country with 10.7 million population, is the worst hit, where cases have risen sharply in the past few weeks. This factor is likely to boost the growth of the viruses segment during the forecast period. The bacteria segment has been segregated into mycoplasma pneumoniae, chlamydophila pneumonia, bordetella pertussis, bordetella parapertussis, and others.
  • Based on panel type, the respiratory panel testing market in EMEA has been classified into syndromic full multiplex panel, and low plex panel. The syndromic full multiplex panel segment accounted for the largest market share in 2020, as syndromic full multiplex panel methods are usually used for the simultaneous detection of two or more target pathogenic DNA or RNA molecules by using several specific primers in a single PCR reaction. Furthermore, syndromic molecular testing has been integrated into routine clinical care, either to provide diagnostic, epidemiological, or patient management information. These factors are anticipated to fuel the growth of the segment in the next few years.
  • In terms of end-user, the respiratory panel testing market in EMEA has been divided into hospital point of-care testing, ref laboratories, hospitals, and others. Increase in incidence of respiratory diseases leads to rise in hospital admissions, which is expected to drive the segment during the forecast period.
  • Each of the segments has been analyzed in detail for market trends, recent trends, and developments, drivers, restraints, opportunities, and useful insights. The respiratory panel testing market report provides current and expected revenue (US$ Mn) for each of these segments from 2021 to 2031, considering 2020 as the base year. The compound annual growth rate (percentage CAGR) has been provided for each segment and market from 2021 to 2031 along with market size estimations.

Regional Overview: Europe and Middle East & Africa Respiratory Panel Testing Market

  • Europe dominated the Respiratory panel testing market in EMEA in 2020, accounting for 85.5% share. Rise in prevalence of respiratory diseases, increase in the geriatric population, and technological advancements in respiratory panel testing are projected to boost the growth of the market in the region during the forecast period. Moreover, increase in incidence of viral infections is anticipated to fuel the growth of the Respiratory panel testing market in Europe in the next few years. For instance, the U.K., Russia, France, Spain, and Italy reported the highest number of confirmed COVID-19 cases during the pandemic.
  • Germany is expected to dominate the respiratory panel testing market in Europe in terms of market share during the forecast period. The country is considered to have robust and well-established medical diagnostics market. Outbreak of COVID-19 placed an enormous public health burden on the country, which is expected to drive the demand for testing panel in the market. In November 2021, the U.K. reported 9,637,190 confirmed coronavirus cases, which is likely to propel the respiratory panel testing market in the country.

Major Players

  • The respiratory panel testing market report concludes with the company profiles section, which includes key information about major players in the Respiratory panel testing market in EMEA
  • Leading players analyzed in the report include
    • F. Hoffmann-La Roche Ltd.
    • bioMerieux SA
    • Medline Industries, Inc.
    • Becton
    • Dickinson & Company
    • altona Diagnostics GmbH
    • CerTest Biotec S.L.
    • Anatolia Geneworks
    • Seegene, Inc.
    • DiaSorin S.p.A. (Luminex)
    • QIAGEN
    • Biocartis
  • Each of these players has been profiled in the respiratory panel testing market report based on parameters such as company overview, financial overview, business strategies, application portfolio, business segments, and recent developments

Europe and Middle East & Africa Respiratory Panel Testing Market Snapshot

Attribute

Detail

Market Size Value in 2020

US$ 1.6 Bn

Market Forecast Value in 2031

US$ 3.1 Bn

Growth Rate (CAGR)

5.1%

Forecast Period

2021–2031

Quantitative Units

US$ Mn for Value

Market Analysis

It includes cross segment analysis as well as regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competitive Landscape

  • Market share analysis by company (2020)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • By Specimen Type
    • Viruses
      • Adenovirus
      • Severe Acute Respiratory Syndrome Coronavirus 2
      • RSV
      • Human Metapneumovirus
      • Rhinovirus/Enterovirus
      • Parainfluenza Virus
      • Flu A
      • Coronavirus
      • Flu B
      • H1N12009
      • Others
    • Bacteria
      • Mycoplasma Pneumoniae
      • Chlamydophila Pneumonia
      • Bordetella Pertussis
      • Bordetella Parapertussis
  • By Panel Type
    • Syndromic Full Multiplex Panel
    • Low Flex Panel
  • By End-user
    • Hospital Point-of-Care Testing
    • Ref Laboratories
    • Hospitals
    • Others

Regions Covered

  • Europe
  • Middle East & Africa

Countries Covered

  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Benelux
  • Poland
  • Sweden
  • Denmark
  • Finland
  • Norway
  • Switzerland
  • Austria
  • Rest of Europe
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Companies Profiled

  • F. Hoffmann-La Roche Ltd.
  • bioMerieux SA
  • Medline Industries, Inc.
  • Becton, Dickinson & Company
  • altona Diagnostics GmbH
  • CerTest Biotec S.L.
  • Anatolia Geneworks
  • Seegene, Inc.
  • DiaSorin S.p.A. (Luminex)
  • QIAGEN
  • Biocartis
  • Other Prominent Players

Customization Scope

Available upon request

Pricing

Available upon request

Europe and Middle East & Africa Respiratory Panel Testing Market – Segmentation

Specimen Type
  • Viruses
    • Adenovirus
    • Severe Acute Respiratory Syndrome
    • RSV
    • Human Metapneumovirus
    • Rhinovirus/Enterovirus
    • Parainfluenza Virus
    • Flu A
    • Coronavirus
    • Flu B
    • HIN1 2009
    • Others
  • Bacteria
    • Mycoplasma Pneumoniae
    • Chlamydophila Pneumonia
    • Bordetella Pertussis
    • Bordetella Parapertussis
Panel Type
  • Syndromic Full Multiplex Panel
  • Low Plex Panel
End-user
  • Hospital Point-of-Care testing
  • Ref Laboratories
  • Hospitals
  • Others
Region
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Finland
    • Norway
    • Denmark
    • Benelux
    • Switzerland
    • Poland
    • Rest of Europe
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Europe and Middle East & Africa Respiratory Panel Testing Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Market Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Europe and Middle East & Africa Respiratory Panel Testing Market Analysis and Forecast, 2018–2031

            4.4.1. Market Revenue Projections (US$ Mn)

    5. Key Insights

        5.1. Key Industry Events (Mergers, Acquisitions, Partnerships, etc.)

        5.2. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)

    6. Europe and Middle East & Africa Respiratory Panel Testing Market Analysis and Forecast, by Specimen Type

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Europe and Middle East & Africa Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

            6.3.1. Viruses

                6.3.1.1. Adenovirus

                6.3.1.2. Severe Acute Respiratory Syndrome

                6.3.1.3. RSV

                6.3.1.4. Human Metapneumovirus

                6.3.1.5. Rhinovirus/Enterovirus

                6.3.1.6. Parainfluenza Virus

                6.3.1.7. Flu A

                6.3.1.8. Others

            6.3.2. Bacteria

                6.3.2.1. Mycoplasma Pneumoniae

                6.3.2.2. Chlamydophila Pneumonia

        6.4. Europe and Middle East & Africa Respiratory Panel Testing Market Attractiveness Analysis, by Specimen Type

    7. Europe and Middle East & Africa Respiratory Panel Testing Market Analysis and Forecast, by Panel Type

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Europe and Middle East & Africa Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

            7.3.1. Syndromic Full Multiplex Panel

            7.3.2. Low Plex Panel

        7.4. Europe and Middle East & Africa Respiratory Panel Testing Market Attractiveness Analysis, by Panel Type

    8. Europe and Middle East & Africa Respiratory Panel Testing Market Analysis and Forecast, by End-user

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Europe and Middle East & Africa Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

            8.3.1. Hospital Point-of-Care testing

            8.3.2. Reference Labs

            8.3.3. Hospitals

            8.3.4. Others

        8.4. Europe and Middle East & Africa Respiratory Panel Testing Market Attractiveness Analysis, by End-user

    9. Europe and Middle East & Africa Respiratory Panel Testing Market Analysis and Forecast, by Region

        9.1. Key Findings

        9.2. Europe and Middle East & Africa Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Region

            9.2.1. Europe

            9.2.2. Middle East & Africa

        9.3. Europe and Middle East & Africa Respiratory Panel Testing Market Attractiveness Analysis, by Country/Region

    10. Europe Respiratory Panel Testing Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

            10.2.1. Viruses

                10.2.1.1. Adenovirus

                10.2.1.2. Severe Acute Respiratory Syndrome

                10.2.1.3. RSV

                10.2.1.4. Human Metapneumovirus

                10.2.1.5. Rhinovirus/Enterovirus

                10.2.1.6. Parainfluenza Virus

                10.2.1.7. Flu A

                10.2.1.8. Others

            10.2.2. Bacteria

                10.2.2.1. Mycoplasma Pneumoniae

                10.2.2.2. Chlamydophila Pneumonia

        10.3. Market Value Forecast, by Panel Type, 2017–2031

            10.3.1. Syndromic Full Multiplex Panel

            10.3.2. Low Plex Panel

        10.4. Market Value Forecast, by End-user, 2017–2031

            10.4.1. Hospital Point-of-Care testing

            10.4.2. Ref Laboratories

            10.4.3. Hospitals

            10.4.4. Others

        10.5. Market Value Forecast, by Country, 2017–2031

            10.5.1. Germany

                10.5.1.1. Market Value Forecast, by Specimen Type, 2017–2031

                    10.5.1.1.1. Viruses

                        10.5.1.1.1.1. Adenovirus

                        10.5.1.1.1.2. Severe Acute Respiratory Syndrome

                        10.5.1.1.1.3. RSV

                        10.5.1.1.1.4. Human Metapneumovirus

                        10.5.1.1.1.5. Rhinovirus/Enterovirus

                        10.5.1.1.1.6. Parainfluenza Virus

                        10.5.1.1.1.7. Flu A

                        10.5.1.1.1.8. Others

                    10.5.1.1.2. Bacteria

                        10.5.1.1.2.1. Mycoplasma Pneumoniae

                        10.5.1.1.2.2. Chlamydophila Pneumonia

                10.5.1.2. Market Value Forecast, by Panel Type, 2017–2031

                    10.5.1.2.1. Syndromic Full Multiplex Panel

                    10.5.1.2.2. Low Plex Panel

                10.5.1.3. Market Value Forecast, by End-user, 2017–2031

                    10.5.1.3.1. Hospital Point-of-Care testing

                    10.5.1.3.2. Ref Laboratories

                    10.5.1.3.3. Hospitals

                    10.5.1.3.4. Others

            10.5.2. U.K.

                10.5.2.1. Market Value Forecast, by Specimen Type, 2017–2031

                    10.5.2.1.1. Viruses

                        10.5.2.1.1.1. Adenovirus

                        10.5.2.1.1.2. Severe Acute Respiratory Syndrome

                        10.5.2.1.1.3. RSV

                        10.5.2.1.1.4. Human Metapneumovirus

                        10.5.2.1.1.5. Rhinovirus/Enterovirus

                        10.5.2.1.1.6. Parainfluenza Virus

                        10.5.2.1.1.7. Flu A

                        10.5.2.1.1.8. Others

                    10.5.2.1.2. Bacteria

                        10.5.2.1.2.1. Mycoplasma Pneumoniae

                        10.5.2.1.2.2. Chlamydophila Pneumonia

                10.5.2.2. Market Value Forecast, by Panel Type, 2017–2031

                    10.5.2.2.1. Syndromic Full Multiplex Panel

                    10.5.2.2.2. Low Plex Panel

                10.5.2.3. Market Value Forecast, by End-user, 2017–2031

                    10.5.2.3.1. Hospital Point-of-Care testing

                    10.5.2.3.2. Ref Laboratories

                    10.5.2.3.3. Hospitals

                    10.5.2.3.4. Others

            10.5.3. France

                10.5.3.1. Market Value Forecast, by Specimen Type, 2017–2031

                    10.5.3.1.1. Viruses

                        10.5.3.1.1.1. Adenovirus

                        10.5.3.1.1.2. Severe Acute Respiratory Syndrome

                        10.5.3.1.1.3. RSV

                        10.5.3.1.1.4. Human Metapneumovirus

                        10.5.3.1.1.5. Rhinovirus/Enterovirus

                        10.5.3.1.1.6. Parainfluenza Virus

                        10.5.3.1.1.7. Flu A

                        10.5.3.1.1.8. Others

                    10.5.3.1.2. Bacteria

                        10.5.3.1.2.1. Mycoplasma Pneumoniae

                        10.5.3.1.2.2. Chlamydophila Pneumonia

                10.5.3.2. Market Value Forecast, by Panel Type, 2017–2031

                    10.5.3.2.1. Syndromic Full Multiplex Panel

                    10.5.3.2.2. Low Plex Panel

                10.5.3.3. Market Value Forecast, by End-user, 2017–2031

                    10.5.3.3.1. Hospital Point-of-Care testing

                    10.5.3.3.2. Ref Laboratories

                    10.5.3.3.3. Hospitals

                    10.5.3.3.4. Others

            10.5.4. Italy

                10.5.4.1. Market Value Forecast, by Specimen Type, 2017–2031

                    10.5.4.1.1. Viruses

                        10.5.4.1.1.1. Adenovirus

                        10.5.4.1.1.2. Severe Acute Respiratory Syndrome

                        10.5.4.1.1.3. RSV

                        10.5.4.1.1.4. Human Metapneumovirus

                        10.5.4.1.1.5. Rhinovirus/Enterovirus

                        10.5.4.1.1.6. Parainfluenza Virus

                        10.5.4.1.1.7. Flu A

                        10.5.4.1.1.8. Others

                    10.5.4.1.2. Bacteria

                        10.5.4.1.2.1. Mycoplasma Pneumoniae

                        10.5.4.1.2.2. Chlamydophila Pneumonia

                10.5.4.2. Market Value Forecast, by Panel Type, 2017–2031

                    10.5.4.2.1. Syndromic Full Multiplex Panel

                    10.5.4.2.2. Low Plex Panel

                10.5.4.3. Market Value Forecast, by End-user, 2017–2031

                    10.5.4.3.1. Hospital Point-of-Care testing

                    10.5.4.3.2. Ref Laboratories

                    10.5.4.3.3. Hospitals

                    10.5.4.3.4. Others

            10.5.5. Spain

                10.5.5.1. Market Value Forecast, by Specimen Type, 2017–2031

                    10.5.5.1.1. Viruses

                        10.5.5.1.1.1. Adenovirus

                        10.5.5.1.1.2. Severe Acute Respiratory Syndrome

                        10.5.5.1.1.3. RSV

                        10.5.5.1.1.4. Human Metapneumovirus

                        10.5.5.1.1.5. Rhinovirus/Enterovirus

                        10.5.5.1.1.6. Parainfluenza Virus

                        10.5.5.1.1.7. Flu A

                        10.5.5.1.1.8. Others

                    10.5.5.1.2. Bacteria

                        10.5.5.1.2.1. Mycoplasma Pneumoniae

                        10.5.5.1.2.2. Chlamydophila Pneumonia

                10.5.5.2. Market Value Forecast, by Panel Type, 2017–2031

                    10.5.5.2.1. Syndromic Full Multiplex Panel

                    10.5.5.2.2. Low Plex Panel

                10.5.5.3. Market Value Forecast, by End-user, 2017–2031

                    10.5.5.3.1. Hospital Point-of-Care testing

                    10.5.5.3.2. Ref Laboratories

                    10.5.5.3.3. Hospitals

                    10.5.5.3.4. Others

            10.5.6. Benelux

                10.5.6.1. Market Value Forecast, by Specimen Type, 2017–2031

                    10.5.6.1.1. Viruses

                        10.5.6.1.1.1. Adenovirus

                        10.5.6.1.1.2. Severe Acute Respiratory Syndrome

                        10.5.6.1.1.3. RSV

                        10.5.6.1.1.4. Human Metapneumovirus

                        10.5.6.1.1.5. Rhinovirus/Enterovirus

                        10.5.6.1.1.6. Parainfluenza Virus

                        10.5.6.1.1.7. Flu A

                        10.5.6.1.1.8. Others

                    10.5.6.1.2. Bacteria

                        10.5.6.1.2.1. Mycoplasma Pneumoniae

                        10.5.6.1.2.2. Chlamydophila Pneumonia

                10.5.6.2. Market Value Forecast, by Panel Type, 2017–2031

                    10.5.6.2.1. Syndromic Full Multiplex Panel

                    10.5.6.2.2. Low Plex Panel

                10.5.6.3. Market Value Forecast, by End-user, 2017–2031

                    10.5.6.3.1. Hospital Point-of-Care testing

                    10.5.6.3.2. Ref Laboratories

                    10.5.6.3.3. Hospitals

                    10.5.6.3.4. Others

            10.5.7. Poland

                10.5.7.1. Market Value Forecast, by Specimen Type, 2017–2031

                    10.5.7.1.1. Viruses

                        10.5.7.1.1.1. Adenovirus

                        10.5.7.1.1.2. Severe Acute Respiratory Syndrome

                        10.5.7.1.1.3. RSV

                        10.5.7.1.1.4. Human Metapneumovirus

                        10.5.7.1.1.5. Rhinovirus/Enterovirus

                        10.5.7.1.1.6. Parainfluenza Virus

                        10.5.7.1.1.7. Flu A

                        10.5.7.1.1.8. Others

                    10.5.7.1.2. Bacteria

                        10.5.7.1.2.1. Mycoplasma Pneumoniae

                        10.5.7.1.2.2. Chlamydophila Pneumonia

                10.5.7.2. Market Value Forecast, by Panel Type, 2017–2031

                    10.5.7.2.1. Syndromic Full Multiplex Panel

                    10.5.7.2.2. Low Plex Panel

                10.5.7.3. Market Value Forecast, by End-user, 2017–2031

                    10.5.7.3.1. Hospital Point-of-Care testing

                    10.5.7.3.2. Ref Laboratories

                    10.5.7.3.3. Hospitals

                    10.5.7.3.4. Others

            10.5.8. Sweden

                10.5.8.1. Market Value Forecast, by Specimen Type, 2017–2031

                    10.5.8.1.1. Viruses

                        10.5.8.1.1.1. Adenovirus

                        10.5.8.1.1.2. Severe Acute Respiratory Syndrome

                        10.5.8.1.1.3. RSV

                        10.5.8.1.1.4. Human Metapneumovirus

                        10.5.8.1.1.5. Rhinovirus/Enterovirus

                        10.5.8.1.1.6. Parainfluenza Virus

                        10.5.8.1.1.7. Flu A

                        10.5.8.1.1.8. Others

                    10.5.8.1.2. Bacteria

                        10.5.8.1.2.1. Mycoplasma Pneumoniae

                        10.5.8.1.2.2. Chlamydophila Pneumonia

                10.5.8.2. Market Value Forecast, by Panel Type, 2017–2031

                    10.5.8.2.1. Syndromic Full Multiplex Panel

                    10.5.8.2.2. Low Plex Panel

                10.5.8.3. Market Value Forecast, by End-user, 2017–2031

                    10.5.8.3.1. Hospital Point-of-Care testing

                    10.5.8.3.2. Ref Laboratories

                    10.5.8.3.3. Hospitals

                    10.5.8.3.4. Others

            10.5.9. Denmark

                10.5.9.1. Market Value Forecast, by Specimen Type, 2017–2031

                    10.5.9.1.1. Viruses

                        10.5.9.1.1.1. Adenovirus

                        10.5.9.1.1.2. Severe Acute Respiratory Syndrome

                        10.5.9.1.1.3. RSV

                        10.5.9.1.1.4. Human Metapneumovirus

                        10.5.9.1.1.5. Rhinovirus/Enterovirus

                        10.5.9.1.1.6. Parainfluenza Virus

                        10.5.9.1.1.7. Flu A

                        10.5.9.1.1.8. Others

                    10.5.9.1.2. Bacteria

                        10.5.9.1.2.1. Mycoplasma Pneumoniae

                        10.5.9.1.2.2. Chlamydophila Pneumonia

                10.5.9.2. Market Value Forecast, by Panel Type, 2017–2031

                    10.5.9.2.1. Syndromic Full Multiplex Panel

                    10.5.9.2.2. Low Plex Panel

                10.5.9.3. Market Value Forecast, by End-user, 2017–2031

                    10.5.9.3.1. Hospital Point-of-Care testing

                    10.5.9.3.2. Ref Laboratories

                    10.5.9.3.3. Hospitals

                    10.5.9.3.4. Others

            10.5.10. Finland

                10.5.10.1. Market Value Forecast, by Specimen Type, 2017–2031

                    10.5.10.1.1. Viruses

                        10.5.10.1.1.1. Adenovirus

                        10.5.10.1.1.2. Severe Acute Respiratory Syndrome

                        10.5.10.1.1.3. RSV

                        10.5.10.1.1.4. Human Metapneumovirus

                        10.5.10.1.1.5. Rhinovirus/Enterovirus

                        10.5.10.1.1.6. Parainfluenza Virus

                        10.5.10.1.1.7. Flu A

                        10.5.10.1.1.8. Others

                    10.5.10.1.2. Bacteria

                        10.5.10.1.2.1. Mycoplasma Pneumoniae

                        10.5.10.1.2.2. Chlamydophila Pneumonia

                10.5.10.2. Market Value Forecast, by Panel Type, 2017–2031

                    10.5.10.2.1. Syndromic Full Multiplex Panel

                    10.5.10.2.2. Low Plex Panel

                10.5.10.3. Market Value Forecast, by End-user, 2017–2031

                    10.5.10.3.1. Hospital Point-of-Care testing

                    10.5.10.3.2. Ref Laboratories

                    10.5.10.3.3. Hospitals

                    10.5.10.3.4. Others

            10.5.11. Norway

                10.5.11.1. Market Value Forecast, by Specimen Type, 2017–2031

                    10.5.11.1.1. Viruses

                        10.5.11.1.1.1. Adenovirus

                        10.5.11.1.1.2. Severe Acute Respiratory Syndrome

                        10.5.11.1.1.3. RSV

                        10.5.11.1.1.4. Human Metapneumovirus

                        10.5.11.1.1.5. Rhinovirus/Enterovirus

                        10.5.11.1.1.6. Parainfluenza Virus

                        10.5.11.1.1.7. Flu A

                        10.5.11.1.1.8. Others

                    10.5.11.1.2. Bacteria

                        10.5.11.1.2.1. Mycoplasma Pneumoniae

                        10.5.11.1.2.2. Chlamydophila Pneumonia

                10.5.11.2. Market Value Forecast, by Panel Type, 2017–2031

                    10.5.11.2.1. Syndromic Full Multiplex Panel

                    10.5.11.2.2. Low Plex Panel

                10.5.11.3. Market Value Forecast, by End-user, 2017–2031

                    10.5.11.3.1. Hospital Point-of-Care testing

                    10.5.11.3.2. Ref Laboratories

                    10.5.11.3.3. Hospitals

                    10.5.11.3.4. Others

            10.5.12. Switzerland

                10.5.12.1. Market Value Forecast, by Specimen Type, 2017–2031

                    10.5.12.1.1. Viruses

                        10.5.12.1.1.1. Adenovirus

                        10.5.12.1.1.2. Severe Acute Respiratory Syndrome

                        10.5.12.1.1.3. RSV

                        10.5.12.1.1.4. Human Metapneumovirus

                        10.5.12.1.1.5. Rhinovirus/Enterovirus

                        10.5.12.1.1.6. Parainfluenza Virus

                        10.5.12.1.1.7. Flu A

                        10.5.12.1.1.8. Others

                    10.5.12.1.2. Bacteria

                        10.5.12.1.2.1. Mycoplasma Pneumoniae

                        10.5.12.1.2.2. Chlamydophila Pneumonia

                10.5.12.2. Market Value Forecast, by Panel Type, 2017–2031

                    10.5.12.2.1. Syndromic Full Multiplex Panel

                    10.5.12.2.2. Low Plex Panel

                10.5.12.3. Market Value Forecast, by End-user, 2017–2031

                    10.5.12.3.1. Hospital Point-of-Care testing

                    10.5.12.3.2. Ref Laboratories

                    10.5.12.3.3. Hospitals

                    10.5.12.3.4. Others

            10.5.13. Austria

                10.5.13.1. Market Value Forecast, by Specimen Type, 2017–2031

                    10.5.13.1.1. Viruses

                        10.5.13.1.1.1. Adenovirus

                        10.5.13.1.1.2. Severe Acute Respiratory Syndrome

                        10.5.13.1.1.3. RSV

                        10.5.13.1.1.4. Human Metapneumovirus

                        10.5.13.1.1.5. Rhinovirus/Enterovirus

                        10.5.13.1.1.6. Parainfluenza Virus

                        10.5.13.1.1.7. Flu A

                        10.5.13.1.1.8. Others

                    10.5.13.1.2. Bacteria

                        10.5.13.1.2.1. Mycoplasma Pneumoniae

                        10.5.13.1.2.2. Chlamydophila Pneumonia

                10.5.13.2. Market Value Forecast, by Panel Type, 2017–2031

                    10.5.13.2.1. Syndromic Full Multiplex Panel

                    10.5.13.2.2. Low Plex Panel

                10.5.13.3. Market Value Forecast, by End-user, 2017–2031

                    10.5.13.3.1. Hospital Point-of-Care testing

                    10.5.13.3.2. Ref Laboratories

                    10.5.13.3.3. Hospitals

                    10.5.13.3.4. Others

            10.5.14. Rest of Europe

                10.5.14.1. Market Value Forecast, by Specimen Type, 2017–2031

                    10.5.14.1.1. Viruses

                        10.5.14.1.1.1. Adenovirus

                        10.5.14.1.1.2. Severe Acute Respiratory Syndrome

                        10.5.14.1.1.3. RSV

                        10.5.14.1.1.4. Human Metapneumovirus

                        10.5.14.1.1.5. Rhinovirus/Enterovirus

                        10.5.14.1.1.6. Parainfluenza Virus

                        10.5.14.1.1.7. Flu A

                        10.5.14.1.1.8. Others

                    10.5.14.1.2. Bacteria

                        10.5.14.1.2.1. Mycoplasma Pneumoniae

                        10.5.14.1.2.2. Chlamydophila Pneumonia

                10.5.14.2. Market Value Forecast, by Panel Type, 2017–2031

                    10.5.14.2.1. Syndromic Full Multiplex Panel

                    10.5.14.2.2. Low Plex Panel

                10.5.14.3. Market Value Forecast, by End-user, 2017–2031

                    10.5.14.3.1. Hospital Point-of-Care testing

                    10.5.14.3.2. Ref Laboratories

                    10.5.14.3.3. Hospitals

                    10.5.14.3.4. Others

        10.6. Market Attractiveness Analysis

            10.6.1. By Specimen Type

            10.6.2. By Panel Type

            10.6.3. By End-user

            10.6.4. By Country/Sub-region

    11. Middle East & Africa Respiratory Panel Testing Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

            11.2.1. Viruses

                11.2.1.1. Adenovirus

                11.2.1.2. Severe Acute Respiratory Syndrome

                11.2.1.3. RSV

                11.2.1.4. Human Metapneumovirus

                11.2.1.5. Rhinovirus/Enterovirus

                11.2.1.6. Parainfluenza Virus

                11.2.1.7. Flu A

                11.2.1.8. Others

            11.2.2. Bacteria

                11.2.2.1. Mycoplasma Pneumoniae

                11.2.2.2. Chlamydophila Pneumonia

        11.3. Market Value Forecast, by Panel Type, 2017–2031

            11.3.1. Syndromic Full Multiplex Panel

            11.3.2. Low Plex Panel

        11.4. Market Value Forecast, by End-user, 2017–2031

            11.4.1. Hospital Point-of-Care testing

            11.4.2. Ref Laboratories

            11.4.3. Hospitals

            11.4.4. Others

        11.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            11.5.1. GCC Countries

                11.5.1.1. Market Value Forecast, by Specimen Type, 2017–2031

                    11.5.1.1.1. Viruses

                        11.5.1.1.1.1. Adenovirus

                        11.5.1.1.1.2. Severe Acute Respiratory Syndrome

                        11.5.1.1.1.3. RSV

                        11.5.1.1.1.4. Human Metapneumovirus

                        11.5.1.1.1.5. Rhinovirus/Enterovirus

                        11.5.1.1.1.6. Parainfluenza Virus

                        11.5.1.1.1.7. Flu A

                        11.5.1.1.1.8. Others

                    11.5.1.1.2. Bacteria

                        11.5.1.1.2.1. Mycoplasma Pneumoniae

                        11.5.1.1.2.2. Chlamydophila Pneumonia

                11.5.1.2. Market Value Forecast, by Panel Type, 2017–2031

                    11.5.1.2.1. Syndromic Full Multiplex Panel

                    11.5.1.2.2. Low Plex Panel

                11.5.1.3. Market Value Forecast, by End-user, 2017–2031

                    11.5.1.3.1. Hospital Point-of-Care testing

                    11.5.1.3.2. Ref Laboratories

                    11.5.1.3.3. Hospitals

                    11.5.1.3.4. Others

            11.5.2. South Africa

                11.5.2.1. Market Value Forecast, by Specimen Type, 2017–2031

                    11.5.2.1.1. Viruses

                        11.5.2.1.1.1. Adenovirus

                        11.5.2.1.1.2. Severe Acute Respiratory Syndrome

                        11.5.2.1.1.3. RSV

                        11.5.2.1.1.4. Human Metapneumovirus

                        11.5.2.1.1.5. Rhinovirus/Enterovirus

                        11.5.2.1.1.6. Parainfluenza Virus

                        11.5.2.1.1.7. Flu A

                        11.5.2.1.1.8. Others

                    11.5.2.1.2. Bacteria

                        11.5.2.1.2.1. Mycoplasma Pneumoniae

                        11.5.2.1.2.2. Chlamydophila Pneumonia

                11.5.2.2. Market Value Forecast, by Panel Type, 2017–2031

                    11.5.2.2.1. Syndromic Full Multiplex Panel

                    11.5.2.2.2. Low Plex Panel

                11.5.2.3. Market Value Forecast, by End-user, 2017–2031

                    11.5.2.3.1. Hospital Point-of-Care testing

                    11.5.2.3.2. Ref Laboratories

                    11.5.2.3.3. Hospitals

                    11.5.2.3.4. Others

            11.5.3. Rest of Middle East & Africa

                11.5.3.1. Market Value Forecast, by Specimen Type, 2017–2031

                    11.5.3.1.1. Viruses

                        11.5.3.1.1.1. Adenovirus

                        11.5.3.1.1.2. Severe Acute Respiratory Syndrome

                        11.5.3.1.1.3. RSV

                        11.5.3.1.1.4. Human Metapneumovirus

                        11.5.3.1.1.5. Rhinovirus/Enterovirus

                        11.5.3.1.1.6. Parainfluenza Virus

                        11.5.3.1.1.7. Flu A

                        11.5.3.1.1.8. Others

                    11.5.3.1.2. Bacteria

                        11.5.3.1.2.1. Mycoplasma Pneumoniae

                        11.5.3.1.2.2. Chlamydophila Pneumonia

                11.5.3.2. Market Value Forecast, by Panel Type, 2017–2031

                    11.5.3.2.1. Syndromic Full Multiplex Panel

                    11.5.3.2.2. Low Plex Panel

                11.5.3.3. Market Value Forecast, by End-user, 2017–2031

                    11.5.3.3.1. Hospital Point-of-Care testing

                    11.5.3.3.2. Ref Laboratories

                    11.5.3.3.3. Hospitals

                    11.5.3.3.4. Others

    12. Competitive Landscape

        12.1. Market Player –Competition Matrix (By Tier and Size of companies)

        12.2. Company Profiles (2020)

            12.2.1. F. Hoffmann-La Roche Ltd.

                12.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                12.2.1.2. Product Portfolio

                12.2.1.3. Financial Overview

                12.2.1.4. Strategic Overview

                12.2.1.5. SWOT Analysis

            12.2.2. bioMerieux SA

                12.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                12.2.2.2. Product Portfolio

                12.2.2.3. Financial Overview

                12.2.2.4. Strategic Overview

                12.2.2.5. SWOT Analysis

            12.2.3. Medline Industries, Inc.

                12.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                12.2.3.2. Product Portfolio

                12.2.3.3. Strategic Overview

                12.2.3.4. SWOT Analysis

            12.2.4. Becton, Dickinson & Company

                12.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                12.2.4.2. Product Portfolio

                12.2.4.3. Financial Overview

                12.2.4.4. Strategic Overview

                12.2.4.5. SWOT Analysis

            12.2.5. altona Diagnostics GmbH

                12.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                12.2.5.2. Product Portfolio

                12.2.5.3. Strategic Overview

                12.2.5.4. SWOT Analysis

            12.2.6. CerTest Biotec S.L.

                12.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                12.2.6.2. Product Portfolio

                12.2.6.3. Strategic Overview

                12.2.6.4. SWOT Analysis

            12.2.7. Anatolia Geneworks

                12.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                12.2.7.2. Product Portfolio

                12.2.7.3. Strategic Overview

                12.2.7.4. SWOT Analysis

            12.2.8. Seegene, Inc.

                12.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                12.2.8.2. Product Portfolio

                12.2.8.3. Strategic Overview

                12.2.8.4. SWOT Analysis

            12.2.9. DiaSorin S.p.A. (Luminex)

                12.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                12.2.9.2. Product Portfolio

                12.2.9.3. Financial Overview

                12.2.9.4. Strategic Overview

                12.2.9.5. SWOT Analysis

            12.2.10. QIAGEN

                12.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                12.2.10.2. Product Portfolio

                12.2.10.3. Financial Overview

                12.2.10.4. Strategic Overview

                12.2.10.5. SWOT Analysis

            12.2.11. Biocartis

                12.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)

                12.2.11.2. Product Portfolio

                12.2.11.3. Strategic Overview

                12.2.11.4. SWOT Analysis

    List of Tables

    Table 01: Europe and Middle East & Africa Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

    Table 02: Europe and Middle East & Africa Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031

    Table 03: Europe and Middle East & Africa Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031

    Table 04: Europe and Middle East & Africa Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031

    Table 05: Europe and Middle East & Africa Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 06: Europe and Middle East & Africa Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Region, 2017–2031

    Table 07: Europe Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 08: Europe Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

    Table 09: Europe Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031

    Table 10: Europe Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031

    Table 11: Europe Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031

    Table 12: Europe Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 13: Germany Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

    Table 14: Germany Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031

    Table 15: Germany Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031

    Table 16: Germany Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031

    Table 17: Germany Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 18: U.K. Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

    Table 19: U.K. Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031

    Table 20: U.K. Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031

    Table 21: U.K. Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031

    Table 22: U.K. Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 23: France Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

    Table 24: France Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031

    Table 25: France Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031

    Table 26: France Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031

    Table 27: France Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 28: Italy Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

    Table 29: Italy Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031

    Table 30: Italy Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031

    Table 31: Italy Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031

    Table 32: Italy Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 33: Spain Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

    Table 34: Spain Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031

    Table 35: Spain Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031

    Table 36: Spain Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031

    Table 37: Spain Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 38: Sweden Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

    Table 39: Sweden Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031

    Table 40: Sweden Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031

    Table 41: Sweden Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031

    Table 42: Sweden Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 43: Denmark Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

    Table 44: Denmark Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031

    Table 45: Denmark Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031

    Table 46: Denmark Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031

    Table 47: Denmark Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 48: Finland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

    Table 49: Finland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031

    Table 50: Finland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031

    Table 51: Finland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031

    Table 52: Finland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 53: Austria Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

    Table 54: Austria Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031

    Table 55: Austria Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031

    Table 56: Austria Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031

    Table 57: Austria Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 58: Switzerland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

    Table 59: Switzerland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031

    Table 60: Switzerland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031

    Table 61: Switzerland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031

    Table 62: Switzerland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 63: Benelux Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

    Table 64: Benelux Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031

    Table 65: Benelux Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031

    Table 66: Benelux Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031

    Table 67: Benelux Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 68: Norway Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

    Table 69: Norway Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031

    Table 70: Norway Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031

    Table 71: Norway Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031

    Table 72: Norway Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 73: Poland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031

    Table 74: Poland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031

    Table 75: Poland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031

    List of Figures

    Figure 01: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value (US$ Mn) Forecast, 2017–2031

    Figure 02: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value Share, by Panel Specimen Type, 2020

    Figure 03: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value Share, by Specimen Type, 2020

    Figure 04: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value Share, by End-user, 2020

    Figure 05: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value Share, by Region, 2020

    Figure 06: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value Share Analysis, by Specimen Type, 2020 and 2031

    Figure 07: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Attractiveness Analysis, by Specimen Type, 2021–2031

    Figure 08: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value (US$ Mn), by Viruses, 2017–2031

    Figure 09: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value (US$ Mn), by Bacteria, 2017–2031

    Figure 10: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value Share Analysis, by Panel Specimen Type, 2020 and 2031

    Figure 11: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Attractiveness Analysis, by Panel Specimen Type, 2021–2031

    Figure 12: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value (US$ Mn), by Syndromic Full Multiplex Panel, 2017–2031

    Figure 13: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value (US$ Mn), by Low Plex Panel, 2017–2031

    Figure 14: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 15: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 16: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value (US$ Mn), by Hospital Point-of-Care Testing, 2017–2031

    Figure 17: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value (US$ Mn), by Ref Laboratories, 2017–2031

    Figure 18: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value (US$ Mn), by Hospitals, 2017–2031

    Figure 19: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value (US$ Mn), by Others, 2017–2031

    Figure 20: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Analysis, 2020 and 2031

    Figure 21: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Attractiveness Analysis, by Region, 2021–2031

    Figure 22: Europe Respiratory Panel Testing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 23: Europe Respiratory Panel Testing Market Value Share, by Country/Sub-region, 2020–2031

    Figure 24: Europe Respiratory Panel Testing Market Attractiveness, by Country/Sub-region, 2021–2031

    Figure 25: Europe Respiratory Panel Testing Market Value Share Analysis, by Specimen Type, 2020 and 2031

    Figure 26: Europe Respiratory Panel Testing Market Attractiveness Analysis, by Specimen Type, 2021–2031

    Figure 27: Europe Respiratory Panel Testing Market Value Share Analysis, by Panel Specimen Type, 2020 and 2031

    Figure 28: Europe Respiratory Panel Testing Market Attractiveness Analysis, by Panel Specimen Type, 2021–2031

    Figure 29: Europe Respiratory Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 30: Europe Respiratory Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 31: Germany Respiratory Panel Testing Market Value Share Analysis, by Specimen Type, 2020 and 2031

    Figure 32: Germany Respiratory Panel Testing Market Attractiveness Analysis, by Specimen Type, 2021–2031

    Figure 33: Germany Respiratory Panel Testing Market Value Share Analysis, by Panel Specimen Type, 2020 and 2031

    Figure 34: Germany Respiratory Panel Testing Market Attractiveness Analysis, by Panel Specimen Type, 2021–2031

    Figure 35: Germany Respiratory Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 36: Germany Respiratory Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 37: U.K. Respiratory Panel Testing Market Value Share Analysis, by Specimen Type, 2020 and 2031

    Figure 38: U.K. Respiratory Panel Testing Market Attractiveness Analysis, by Specimen Type, 2021–2031

    Figure 39: U.K. Respiratory Panel Testing Market Value Share Analysis, by Panel Specimen Type, 2020 and 2031

    Figure 40: U.K. Respiratory Panel Testing Market Attractiveness Analysis, by Panel Specimen Type, 2021–2031

    Figure 41: U.K. Respiratory Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 42: U.K. Respiratory Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 43: France Respiratory Panel Testing Market Value Share Analysis, by Specimen Type, 2020 and 2031

    Figure 44: France Respiratory Panel Testing Market Attractiveness Analysis, by Specimen Type, 2021–2031

    Figure 45: France Respiratory Panel Testing Market Value Share Analysis, by Panel Specimen Type, 2020 and 2031

    Figure 46: France Respiratory Panel Testing Market Attractiveness Analysis, by Panel Specimen Type, 2021–2031

    Figure 47: France Respiratory Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 48: France Respiratory Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 49: Italy Respiratory Panel Testing Market Value Share Analysis, by Specimen Type, 2020 and 2031

    Figure 50: Italy Respiratory Panel Testing Market Attractiveness Analysis, by Specimen Type, 2021–2031

    Figure 51: Italy Respiratory Panel Testing Market Value Share Analysis, by Panel Specimen Type, 2020 and 2031

    Figure 52: Italy Respiratory Panel Testing Market Attractiveness Analysis, by Panel Specimen Type, 2021–2031

    Figure 53: Italy Respiratory Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 54: Italy Respiratory Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 55: Spain Respiratory Panel Testing Market Value Share Analysis, by Specimen Type, 2020 and 2031

    Figure 56: Spain Respiratory Panel Testing Market Attractiveness Analysis, by Specimen Type, 2021–2031

    Figure 57: Spain Respiratory Panel Testing Market Value Share Analysis, by Panel Specimen Type, 2020 and 2031

    Figure 58: Spain Respiratory Panel Testing Market Attractiveness Analysis, by Panel Specimen Type, 2021–2031

    Figure 59: Spain Respiratory Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 60: Spain Respiratory Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 61: Sweden Respiratory Panel Testing Market Value Share Analysis, by Specimen Type, 2020 and 2031

    Figure 62: Sweden Respiratory Panel Testing Market Attractiveness Analysis, by Specimen Type, 2021–2031

    Figure 63: Sweden Respiratory Panel Testing Market Value Share Analysis, by Panel Specimen Type, 2020 and 2031

    Figure 64: Sweden Respiratory Panel Testing Market Attractiveness Analysis, by Panel Specimen Type, 2021–2031

    Figure 65: Sweden Respiratory Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 66: Sweden Respiratory Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 67: Denmark Respiratory Panel Testing Market Value Share Analysis, by Specimen Type, 2020 and 2031

    Figure 68: Denmark Respiratory Panel Testing Market Attractiveness Analysis, by Specimen Type, 2021–2031

    Figure 69: Denmark Respiratory Panel Testing Market Value Share Analysis, by Panel Specimen Type, 2020 and 2031

    Figure 70: Denmark Respiratory Panel Testing Market Attractiveness Analysis, by Panel Specimen Type, 2021–2031

    Figure 71: Denmark Respiratory Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 72: Denmark Respiratory Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 73: Finland Respiratory Panel Testing Market Value Share Analysis, by Specimen Type, 2020 and 2031

    Figure 74: Finland Respiratory Panel Testing Market Attractiveness Analysis, by Specimen Type, 2021–2031

    Figure 75: Finland Respiratory Panel Testing Market Value Share Analysis, by Panel Specimen Type, 2020 and 2031

Copyright © Transparency Market Research, Inc. All Rights reserved